Man Group’s iBio IBIO Stock Holding History

Man Group’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-415	Closed	-$114K	–	2251
2021 Q4	$114K	Hold	415	–	–	﹤0.01%	1870
2021 Q3	$220K	Buy	415 +150	+57%	+$93.4K	﹤0.01%	1739
2021 Q2	$200K	Buy	+265	New	+$193K	﹤0.01%	1803

Other funds holding IBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Man Group's IBIO Position: Q1 2022 in Review

Man Group sold out of iBio (IBIO) in Q1 2022, closing a stake of 415 shares — an estimated $114K sold.

Man Group first reported a position in IBIO in Q2 2021 and held it in 3 quarters. The position peaked at $220K in Q3 2021. 70 funds tracked by Wall St. Rank hold IBIO as of Q1 2022.

Man Group reported no remaining iBio position as of Q1 2022 after selling out during the quarter.
Man Group sold 415 iBio shares in Q1 2022, an estimated $114K.
Man Group first reported a position in iBio in Q2 2021 and held it in 3 quarters.
Man Group's iBio position peaked at $220K in Q3 2021.
70 funds tracked by Wall St. Rank held iBio as of Q1 2022.

Based on Man Group's 13F filing for Q1 2022, filed 16 May 2022.